Azithromycin SR

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Upper Respiratory Tract Infection

Conditions

Upper Respiratory Tract Infection

Trial Timeline

Nov 1, 2006 → May 1, 2007

NCT ID

NCT00393835

About Azithromycin SR

Azithromycin SR is a phase 3 stage product being developed by Pfizer for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00393835. Target conditions include Upper Respiratory Tract Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00998309	Pre-clinical	Completed	Oct 1, 2009	Jan 1, 2011	Bacterial Infections
NCT00393835	Phase 3	Completed	Nov 1, 2006	May 1, 2007	Upper Respiratory Tract Infection
NCT00360464	Phase 3	Completed	Oct 1, 2006	Jun 1, 2007	Acute Bronchitis
NCT00360295	Phase 3	Completed	Sep 1, 2006	May 1, 2007	Pneumonia, Community-Acquired

Competing Products

20 competing products in Upper Respiratory Tract Infection

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	52
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	85
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	33
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	52
BOTOX	AbbVie	Approved	85
MK-3475 and BCG	Merck	Phase 2	52
Montelukast + Placebo	Merck	Approved	85
Muntelukast + Placebo	Merck	Phase 3	77
IFF flavor 316 282, Paracetamol, Pseudoephedrine	Novartis	Phase 3	77
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	77
diclofenac potassium + nimesulide	Novartis	Approved	85
Diclofenac gel	Novartis	Approved	85
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin	Novartis	Phase 3	77
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	76
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	51
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	38
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	82
Botulinum toxin type A	Ipsen	Phase 3	74

Other Products from Pfizer